ANIP Logo

ANI Pharmaceuticals, Inc. (ANIP) 

NASDAQ
Market Cap
$1.17B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
433 of 774
Rank in Industry
21 of 47

Largest Insider Buys in Sector

ANIP Stock Price History Chart

ANIP Stock Performance

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through …

Insider Activity of ANI Pharmaceuticals, Inc.

Over the last 12 months, insiders at ANI Pharmaceuticals, Inc. have bought $0 and sold $36.23M worth of ANI Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at ANI Pharmaceuticals, Inc. have bought $562,034 and sold $29.38M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,224 shares for transaction amount of $199,997 was made by Lalwani Nikhil (PRESIDENT & CEO) on 2022‑03‑21.

List of Insider Buy and Sell Transactions, ANI Pharmaceuticals, Inc.

2024-11-15SaleHEAD OF RARE DISEASE
6,500
0.0304%
$57.70$375,050-2.62%
2024-11-13SaleSR. VP, GENERAL COUNSEL & SEC.
250
0.0012%
$61.36$15,340-6.67%
2024-10-14SaleSR. VP, GENERAL COUNSEL & SEC.
250
0.0012%
$57.19$14,298+0.52%
2024-09-13SaleSR. VP, GENERAL COUNSEL & SEC.
250
0.0012%
$56.82$14,205+0.08%
2024-08-13SaleSR. VP, GENERAL COUNSEL & SEC.
250
0.0012%
$59.62$14,9050.00%
2024-07-18SaleHEAD OF R&D, COO-NOVITIUM OPS
2,743
0.0132%
$62.00$170,066-2.75%
2024-07-17SaleHEAD OF R&D, COO-NOVITIUM OPS
14,257
0.0682%
$63.16$900,472-5.26%
2024-07-16SaleHEAD OF R&D, COO-NOVITIUM OPS
22,000
0.103%
$64.27$1.41M-7.08%
2024-07-15SaleHEAD OF R&D, COO-NOVITIUM OPS
11,000
0.0508%
$63.38$697,1800.00%
2024-07-12SaleSR. VP, GENERAL COUNSEL & SEC.
250
0.0012%
$64.91$16,2280.00%
2024-07-01SaleSVP - CORP. DEV. & STRATEGY
20,000
0.0924%
$63.44$1.27M0.00%
2024-06-21SaleHEAD OF R&D, COO-NOVITIUM OPS
20,000
0.0866%
$58.90$1.18M+2.61%
2024-06-20SaleHEAD OF R&D, COO-NOVITIUM OPS
11,447
0.0503%
$59.86$685,217+0.93%
2024-06-18SaleHEAD OF R&D, COO-NOVITIUM OPS
10,607
0.0474%
$60.76$644,481-1.50%
2024-06-17SaleHEAD OF R&D, COO-NOVITIUM OPS
7,946
0.0359%
$61.41$487,964-2.97%
2024-06-13SaleSR. VP, GENERAL COUNSEL & SEC.
250
0.0012%
$63.80$15,950-5.01%
2024-06-05SaleSVP, GENERICS
2,985
0.0142%
$67.00$199,995-9.84%
2024-06-04SaleSVP & CFO
5,000
0.0234%
$63.58$317,900-6.75%
2024-06-03SaleSVP - CORP. DEV. & STRATEGY
20,000
0.0969%
$64.41$1.29M-4.83%
2024-05-21SaleHEAD OF RARE DISEASE
2,000
0.0095%
$61.61$123,220-1.60%

Insider Historical Profitability

12.79%
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS
632620
3.0099%
$55.69156+24.75%
Lalwani NikhilPRESIDENT & CEO
377505
1.7961%
$55.6915+31.46%
Gassert ChadSVP - CORP. DEV. & STRATEGY
193226
0.9193%
$55.69110+29.72%
Pera Antonio Rdirector
26627
0.1267%
$55.6912<0.0001%
MORGENSTERN VICTOR Adirector
455571
2.1675%
$55.6920+243.13%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$174.99M12.082.53M+0.26%+$445,888.50<0.01
The Vanguard Group$90.31M6.231.31M+1.35%+$1.21M<0.01
Helm Capital Management LLC$66.26M4.57958,533-14.8%-$11.51M1.96
Deep Track Capital Lp$56.82M3.92822,001+37%+$15.35M0.26
Dimensional Fund Advisors$42.11M2.91609,173+2.95%+$1.21M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.